Home / Retatrutide / Side effects

Retatrutide side effects

Phase 3, not approved Retatrutide has no FDA label. Rates below are from Eli Lilly's TRIUMPH-1 phase 3 topline (May 2026, 80 weeks) as reported by the trade press; the peer-reviewed paper confirms stomach and gut effects were most common.

Short answer: In the phase 3 trial, stomach and gut effects were most common and rose with dose: nausea in 42% at 12 mg vs 15% on placebo. A skin sensitivity or burning sensation (dysesthesia) was reported by about 12% at the two higher doses. 11.3% stopped because of side effects at 12 mg, vs 4.9% on placebo.

How common each side effect is

Side effectPlacebo4 mg9 mg12 mg
Nausea14.8%28.6%38.4%42.4%
Diarrhea13.5%25.2%34.1%32.0%
Constipation10.9%23.8%25.9%26.1%
Vomiting4.8%10.6%22.8%25.3%
Dysesthesia (skin sensitivity, burning)0.9%5.1%12.3%12.5%
Stopped because of side effects4.9%4.1%6.9%11.3%

TRIUMPH-1, adults with obesity and no diabetes. Company topline via trade press; not yet checked against the full paper.

Other numbers worth knowing

Trial size2,339 adults, 80 weeks (TRIUMPH-1)
Phase 2 (2023)Side effects were mainly stomach and gut, dose-related, mostly mild to moderate, and fewer when starting at 2 mg instead of 4 mg
Heart rate (phase 2)Rose with dose, peaked at 24 weeks, then declined
Long-term safetyUnknown: there is no label and no post-approval data

When side effects happen

In phase 2, starting at a lower dose (2 mg) reduced stomach and gut side effects. TRIUMPH-1 started at 2 mg and stepped up every 4 weeks.

Not medical advice. Contact your prescriber about side effects that are severe or do not go away, and get urgent care for severe stomach pain, signs of an allergic reaction or trouble breathing.

More on Retatrutide: dosage and status ·units calculator

Side effects of: Tirzepatide · Semaglutide · BPC-157

Questions

What are the most common side effects of retatrutide?
Nausea, diarrhea, constipation and vomiting. In TRIUMPH-1, nausea affected 42.4% at 12 mg vs 14.8% on placebo, according to the company topline.
Is retatrutide harder to tolerate than tirzepatide?
They have not been compared head to head. In their own trials, about 11% stopped retatrutide 12 mg because of side effects, vs about 7% on tirzepatide 15 mg; different trials and populations, so treat that as a rough guide only.
What is retatrutide dysesthesia?
An abnormal skin sensation such as tingling, burning or sensitivity to touch. It was reported by about 12% at 9 and 12 mg vs 0.9% on placebo. Lilly described it as generally mild to moderate.
Are retatrutide side effects from research peptide sellers the same?
Nobody knows. Trial data come from a pharmaceutical-grade product at known doses. Products sold online as 'research' retatrutide are not checked for identity, purity or dose, and the FDA has sent warning letters to sellers.

Sources

  1. Jastreboff et al. Retatrutide for the treatment of obesity (TRIUMPH-1). NEJM 2026 (PubMed)
  2. HCPLive: Retatrutide meets weight-loss endpoints in phase 3 obesity trial (Lilly topline, May 2026)
  3. Jastreboff et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. NEJM 2023
  4. FDA warning letter to TXP Innovations (Tex Peptides), Aug 24, 2026

Last checked 2026-11-16. How we pick and check sources: methodology.